ASH 2025
Update: 2025-12-11
Description
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
